Inside Cipla’s battle with ‘superbugs’ as antibiotic resistance rises in India

Cipla’s Global Chief Medical Officer Dr. “Since we started our work (antimicrobial drug resistance), our strategic plan has been to introduce three to four products on a 5 -year horizon.” He said.

“I think this will be a long -term strategy. As a company that focuses on India, there is no option to be in an antibiotic segment,” he added.

Microorganisms such as antimicrobial drug resistance, bacteria or fungus occur when they develop to resist drugs designed to kill or prevent them. This ‘super insects’ neutralizes existing treatments and may cause an increase in infection and may cause death.

According to a Lancet study, bacterial antimicrobial resistance was associated with 4,71 million global deaths in 2021. This can rise to 39 million by 2050. India, one of the world’s largest antibiotic markets, also has one of the highest drug resistance loads.

Excessive use of antibiotics caused increasing resistances in society, while new drug development did not adapt to the increasing threat.

Gogtay said Gogtay, although we know that in the future, antibiotic -resistant infections will probably kill more people than cancer infections, Gog said Gogtay, Gogtay said Gogtay.

Globally, the focus of development has shifted to treatments such as cancer and obesity from infected and antibiotics, and most major pharmaceutical companies have emerged from antibiotic research.

Cipla’s pipeline

Cipla launched two drugs targeting bacterial AMR last year. In May, it was the first company to launch a plasomycin marketed under the Zemdri brand in India, a new anti-microbial with activity against multi-drug-resistant bacteria and clinical activity in complex urinary tract infections (CUTI).

The clinical efficacy expresses how well a drug or treatment method achieves its intended effect on controlled clinical studies.

Last year, he established a partnership with the Chennai-based Orchid Pharma Ltd to start the new antibiotic Sefime-anmetazobactam approved for the treatment of pneumonia-related pneumonia-related pneumonia-related pneumonia.

This year, the company plans to start a non -antibiotic that can be used to prevent Cutis without risk of resistance. Gogtay, “We work with a partner and the product is approved in India. We will start this product in India in a short time,” he said.

For 2024-25, with jeep, La27,548 Crore, 8% annually, post -tax profit increased by 28% La5.273 Crore.

How big is the market?

General Sunday for anti-infective drugs in India LaAccording to Pharmarack, the Pharma Intelligence Platform, 26,824 Crore in May. Antibiotics explained the sales value of this La23.127 Crore. (Matte sales, total sales in the last 12 months, is calculated on the basis of rolling.)

However, according to experts, it is difficult to be zero in the size of the markets that target drug -resistant bacteria. Drugs targeting antimicrobial drug resistance are given after proven that the first or second antibiotic line is ineffective in the treatment of a patient. However, as the resistance increases, the market grows.

“What they are trying to do here (jeep) is to define certain areas that may be meaningful for a while and try to start early. They are trying to be early in an area that may be much more relevant in the future,

Anti-infective drugs form a key therapy segment for CIPLA after respiratory, cardiac and urology. “Most players who are strong in anti-infective therapy may be looking at this area.”

In addition to Cipla, Wockhardt Ltd also sharpened two new antibiotic pipeline and antimicrobial drug resistance.

As in July 3, the jeeps and shares decreased by about 1.4% since the beginning of the year, while WockhardT shares increased by 20% in NSE. The Nifty Pharma Index fell from a year to more than 5%.